Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.
about
Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcomaEfficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).Preventing aging with stem cell rejuvenation: Feasible or infeasible?
P2860
Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Senescence bypass in mesenchym ...... enescence therapy in sarcomas.
@en
type
label
Senescence bypass in mesenchym ...... enescence therapy in sarcomas.
@en
prefLabel
Senescence bypass in mesenchym ...... enescence therapy in sarcomas.
@en
P2860
P1476
Senescence bypass in mesenchym ...... enescence therapy in sarcomas.
@en
P2093
Kanya Honoki
Toshifumi Tsujiuchi
P2860
P304
P356
10.1586/14737140.2013.820010
P577
2013-08-01T00:00:00Z